

WKN: 941135 / ISIN: LU0119891520

MEDICAL BioHealth

THE BIOTECH FUND MANAGED BY SCIENTISTS
SMALL COMPANIES AGAINST MAJOR ILLNESSES

FUND MANAGER

Mario Linimeier



Managing Partner Mario Linimeier is a molecular biologist and business economist and has been managing MEDICAL BioHealth since 2017. He studied at the University of Vienna, Kepler University Linz and Seoul National University.

Kristoffer Karl Unterbruner



Kristoffer Karl Unterbruner has been co-managing the MEDICAL BioHealth fund since 2022. A biotechnologist by training, he also specialises in immunology and gene therapy approaches.



Investment in a healthy future:
Each company we have selected has the potential to **significantly improve existing therapies or make diseases treatable for the first time.**


INVESTMENT STRATEGY

- **Groundbreaking progress:**
Countless therapeutic areas are experiencing a turning point thanks to technological advances
- **Promising biotech companies:**
Development of novel and modern active substances against diseases
- **Focus on small and medium-sized companies:** Above-average innovative strength with high value creation dynamics

IN PROFILE

- **Scientists as portfolio managers:** understanding complex interrelationships and early identification of medical breakthroughs
- **Successful investment history:** For over 20 years with a significant outperformance compared to healthcare indices by investing in a broadly diversified investment portfolio (70-100 individual stocks)
- **Potential for the future:** Biotechnology in conjunction with technological developments (A.I., digitalisation) is opening up unimagined possibilities for our health as a result of medical progress

PERFORMANCE SINCE ISSUE 30/10/2000 (AS AT Q4/2024)



As at: 30/12/2024; Source: vwd; Price indices in EUR; The previous day's closing prices were used to calculate the index performance and the exchange rate conversion. As the fund is mainly invested in North America, the time difference was into account. Fund: Performance calculation based on gross performance (BVI method). The front-end load (for investment and reinvestment) was not taken into account, nor were individual costs such as custody fees included. If the front-end load and custody fees were included, the performance would be lower. Past performance is not an indicator of future performance and is no guarantee of future success.

PERFORMANCE 5 YEARS (IN %; AS AT Q4/2024)

	Jan	Feb	Mar	April	May	June	July	Aug	Sep	Oct	Nov	Dec	Year
2019	11.9	8.7	2.5	0.2	-2.5	2.7	3.0	-3.9	-3.1	2.6	11.9	4.8	44.1
2020	-2.4	-3.0	-12.1	24.2	5.6	1.0	-5.1	-2.5	3.3	2.3	7.7	1.4	17.5
2021	5.6	-2.3	-2.4	-0.3	-4.2	4.9	-5.4	4.3	-1.4	0.9	-7.4	0.1	-8.3
2022	-12.4	2.3	3.6	-5.7	-8.3	9.3	8.6	6.9	-2.7	1.7	-6.9	-1.0	-7.2
2023	4.6	-0.3	-7.7	2.3	7.2	2.8	5.3	-3.5	-3.1	-9.7	2.2	20.9	19.3
2024	2.7	11.2	-3.3	-5.4	-0.2	3.7	2.8	0.2	-3.1	0.7	4.4	-4.8	7.9

Status: 30/12/2024; source: Anevis GmbH; Calculation based on gross performance (BVI method), i.e. without taking the front-end load into account. Past performance is not a reliable indicator of future performance. The gross performance (BVI method) takes into account all costs incurred at fund level (e.g. the management fee), excluding the front-end load. Further costs may be incurred individually at client level (e.g. custody account fees, commissions and other charges). Model calculation (net): An investor wishes to units for EUR 1000. With a maximum front-end load of 5%, he must a one-off fee of EUR 50 at the time of purchase. In addition, custody account costs may be incurred which reduce the performance. The custody account costs can be found in your bank's list of prices and services.

NEW INNOVATIVE TREATMENT OPTIONS ARE BEING DEVELOPED BY **BIOTECH COMPANIES** TODAY

Biotechnology sector of the future - quantum leaps in medicine

Groundbreaking progress expected in many therapeutic areas

The **billion-euro attack** on **Cancer diseases**

More than **300 million people** with **rare diseases**



Autoimmune diseases: High demand for **new therapies**

Diseases of the **central nervous system:** **new approaches** against Alzheimer & Co.

Cardiometabolic diseases: Cardiovascular and metabolic diseases as **Cause of death #1**

» *"We continuously analyse and evaluate around 900 small and medium-sized companies that many investors do not even on their radar. Above-average growth is primarily generated by these small, research-orientated companies".*

Mario Linimeier, Managing Partner at Medical Strategy GmbH



www.medicalstrategy.de



Opportunities

- Participation in the global growth of the healthcare market
- Portfolio of carefully selected companies
- Focus on developers of innovative therapies
- Expertise of an interdisciplinary team of experts with a scientific background

Risiken

- Price risk
- Misjudgements in investment selection are possible
- Specific risks of drug development
- Market risk
- Liquidity risks
- Currency risks

Disclaimer: This document is a marketing communication. It cannot replace an individual consultation, does not constitute investment advice or a solicitation to buy or sell shares and serves solely to describe the product. It is not a financial analysis and therefore does not have to fulfil all legal requirements regarding the impartiality of financial analyses. It is therefore not subject to a ban on trading prior to the publication of financial analyses. Further detailed information on the opportunities and risks can be found in the sales prospectus and the key information document. The sales prospectus, the key information document and the associated semi-annual and annual reports are the sole binding basis for the purchase of fund units. They are available from the management company Hauck & Aufhäuser Fund Services S.A., 1c, rue Gabriel Lippmann 5365 Munsbach, Luxembourg and at <https://medicalstrategy.de/fonds/medical-bio-health>. The statements of opinion contained in this product information reflect the current, carefully prepared assessment of Medical Strategy GmbH; these may change at any time without prior notice. Past performance is not a reliable indicator current and future performance and losses are possible. Investment funds are subject to market-related price fluctuations, which can lead to losses of the capital invested.